Standout Papers
Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
2008
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
2012
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
2008
eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
2012
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
2004 Science
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
2009
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
2008
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
2015
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
2009
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
2007
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
2003
Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy
2011
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
2011
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells
2005
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Activation of Akt-1 (PKB-α) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion
2004
Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
2006
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
2009
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
2012
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
2009
Hallmarks of Cancer: The Next Generation
2011 Standout
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
2012
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
2004
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
2005
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
2003 Nature
Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche
2017
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
2003
EGFR Antagonists in Cancer Treatment
2008 Standout
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model
2008
Common corruption of the mTOR signaling network in human tumors
2008
ErbB-targeted therapeutic approaches in human cancer
2003
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Angiogenesis in pre-malignant conditions
2009
RIM Proteins Tether Ca2+ Channels to Presynaptic Active Zones via a Direct PDZ-Domain Interaction
2011 StandoutNobel
Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
2003
Analysis of the genome to personalize therapy for melanoma
2010
Epithelial-mesenchymal transition in tissue repair and fibrosis
2016
Comparing antibody and small-molecule therapies for cancer
2006
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Pro-senescence therapy for cancer treatment
2011
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
2012
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
mTOR and cancer: many loops in one pathway
2009
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
mTOR inhibitors in the treatment of cancer
2008
TGFβ signalling in context
2012 Standout
Trastuzumab: triumphs and tribulations
2007
Crystal Structure of GRIP1 PDZ6-Peptide Complex Reveals the Structural Basis for Class II PDZ Target Recognition and PDZ Domain-mediated Multimerization
2003
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer
2003
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways
2003
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
2009 Standout
Monoclonal antibodies: versatile platforms for cancer immunotherapy
2010
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Antibodies in oncology
2011
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
2009
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
Follicular B helper T cells in antibody responses and autoimmunity
2005
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
2005
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
2014
4E-BP Extends Lifespan upon Dietary Restriction by Enhancing Mitochondrial Activity in Drosophila
2009
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
2006
Antibody therapy of cancer
2012 Standout
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
2010
TGFβ signalling: a complex web in cancer progression
2010
Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation
2004
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer
2004
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Emergence of the Phosphoinositide 3-Kinase-Akt- Mammalian Target of Rapamycin Axis in Transforming Growth Factor-β-Induced Epithelial-Mesenchymal Transition
2010
Autocrine TGF-β Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through Sry-Related HMG-Box Factors
2009
Notch3 is important for TGF-β-induced epithelial–mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1
2014
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The Transcription Factors Snail and Slug Activate the Transforming Growth Factor-Beta Signaling Pathway in Breast Cancer
2011
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
2006
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
2005
TGF-β signaling and epithelial–mesenchymal transition in cancer progression
2012
14‐3‐3 suppresses the nuclear localization of threonine 157‐phosphorylated p27Kip1
2004
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction
2009
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Gefitinib — a novel targeted approach to treating cancer
2004
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
2012
Targeting epidermal growth factor receptor—are we missing the mark?
2003
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
2003
p53-Dependent Translational Control of Senescence and Transformation via 4E-BPs
2009
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
2012
Mechanisms of cutaneous toxicities to EGFR inhibitors
2006
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
2005
TGFβ in Cancer
2008 Standout
Where next for gefitinib in patients with lung cancer?
2006
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
2010
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
2003
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
2003
LRP1 Functions as an Atheroprotective Integrator of TGFβ and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome
2007
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
CDK Inhibitors: Cell Cycle Regulators and Beyond
2008
Scar wars: mapping the fate of epithelial–mesenchymal–myofibroblast transition
2011
Solution Structure of the RIM1α PDZ Domain in Complex with an ELKS1b C-terminal Peptide
2005 StandoutNobel
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma
2009
The PI3K Pathway in Human Disease
2017 Standout
Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow
2004
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors
2003
Gastrointestinal toxicities of novel agents in cancer therapy
2009
Id-1 activates Akt-mediated Wnt signaling and p27Kip1 phosphorylation through PTEN inhibition
2008
Lack of PTEN sequesters CHK1 and initiates genetic instability
2005
Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy
2004
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
PDGF receptors as cancer drug targets
2003
A Hypoxia-Controlled Cap-Dependent to Cap-Independent Translation Switch in Breast Cancer
2007
Pten Dose Dictates Cancer Progression in the Prostate
2003
Ras-dependent carbon metabolism and transformation in mouse fibroblasts
2006
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
2005
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study
2004
Oncogenic PI3K deregulates transcription and translation
2005
Smad3‐mediated recruitment of the methyltransferase SETDB1/ESET controls Snail1 expression and epithelial–mesenchymal transition
2017
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
2004
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
2009
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
2004
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
2003
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
2007
eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation
2016 StandoutNatureNobel
2016
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
2003
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
2011 Science
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
2003
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
2005
Tyrosine Kinases as Targets for Cancer Therapy
2005
High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan
2004
Signaling mechanisms of the epithelial-mesenchymal transition
2014
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
2009
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
2004
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
2004
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
2005
A family of RIM-binding proteins regulated by alternative splicing: Implications for the genesis of synaptic active zones
2002 StandoutNobel
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
2007
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
2011
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
2005
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
2008
The Ins and Outs of the Epithelial to Mesenchymal Transition in Health and Disease
2011
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
2002
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
eIF4E, the mRNA cap-binding protein: from basic discovery to translational researchThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Systems and Chemical Biology, and has undergone the Journal's usual peer review process.
2008
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
The regulation of TGFβ signal transduction
2009
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
2005
Mechanism and role of PDZ domains in signaling complex assembly
2001
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Phase II Trial of Gefitinib in Recurrent Glioblastoma
2003
Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial
2004
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
2016
Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGFβ stimulation in cancer
2017
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
2016
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
Claudins and the Modulation of Tight Junction Permeability
2013 Standout
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2003
Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy
2003
Roles for Growth Factors in Cancer Progression
2010
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
2003
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
2010
Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice
2008 StandoutNobel
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
2005
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
2004
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
2011
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
2005
De novo design of protein logic gates
2020 StandoutScienceNobel
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
2008
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004
Works of Federico Rojo being referenced
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
2012
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
2003
Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
2006
Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR
2005
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)
2003
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
2002
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
2007
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
2001
p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer
2006
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
2002
A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition
2009
C-MET as a new therapeutic target for the development of novel anticancer drugs
2010
Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer
2006
Regulatory and Functional Connection of Microphthalmia-Associated Transcription Factor and Anti-Metastatic Pigment Epithelium Derived Factor in Melanoma
2014
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
2008 Standout
High TGFβ-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene
2007
TACE is required for the activation of the EGFR by TGF-α in tumors
2003
Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)
2004
Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)
2004
High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
2014
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
2002
The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein
2000
4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis
2007
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
2001
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
2001
Reduction of Cytosolic p27Kip1 Inhibits Cancer Cell Motility, Survival, and Tumorigenicity
2006
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
2005
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
2008
A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC)
2006
4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications
2007
A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors
2005
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
2004
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study
2008
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
2003
Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)
2004
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002